NeuroOne beats Q1 estimates, raises 2026 outlook on OneRF momentum
Medical device company reports stronger-than-expected earnings as trigeminal nerve ablation system gains traction
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) beat first-quarter expectations and raised its fiscal year 2026 revenue outlook, signaling growing momentum for the company's OneRF ablation system as it gains commercial traction in treating chronic pain conditions.
The Eden Prairie, Minnesota-based medical technology company reported revenue of $2.9 million for the quarter, surpassing analyst estimates of $2.7 million by 7.5%. The company recorded a loss of three cents per share, better than the expected loss of 3.5 cents per share, representing a 14.3% beat on the bottom line.
Management lifted its full-year 2026 revenue guidance to $10.5 million, a 17% increase year-over-year, reflecting confidence in the growing adoption of its minimally invasive nerve ablation technology. The updated outlook comes as nearly half of all ablation procedures performed since the OneRF launch occurred during the first quarter, according to the company's earnings announcement.
"Our OneRF Trigeminal Nerve Ablation System is gaining meaningful traction, with initial clinical results showing excellent patient outcomes," said Dave Rosa, chief executive officer of NeuroOne. The system received FDA 510(k) clearance in August 2025 for treating trigeminal neuralgia, a debilitating condition affecting approximately 150,000 Americans annually.
The company reported that nine cases have been completed using the trigeminal nerve ablation system, with all patients achieving pain-free status following the procedure. The OneRF technology delivers targeted radiofrequency energy to ablate specific nerve fibers, interrupting pain signaling through a minimally invasive approach that may allow for reduced procedural time and improved patient safety.
Despite the strong top-line performance, profitability metrics showed some pressure. Gross margin compressed to 54.2% compared to 58.9% in the prior-year period, reflecting the ongoing investment in commercialization efforts. Cash and cash equivalents declined to $3.6 million at quarter-end, while the company posted a net loss of $1.4 million, contrasting with net income of $1.8 million in the same period last year.
The year-over-year decline in profitability was largely attributable to the absence of a $3 million one-time license revenue benefit that boosted the prior-year comparison. Excluding this non-recurring item, the underlying business showed improvement as core product revenue accelerated.
NeuroOne's shares have gained approximately 8% in recent trading, reflecting investor enthusiasm for the earnings beat and guidance raise. The company's market capitalization stands at approximately $34 million, with analysts maintaining a price target of $2.23, representing significant upside from current levels around 81 cents per share.
The commercial momentum for OneRF comes at a critical juncture for NeuroOne, which has partnered with Zimmer Biomet to distribute its brain ablation technology. The trigeminal nerve system represents an expansion beyond the company's core neuroscience offerings into the broader pain management market.
Looking ahead, investors will focus on the company's ability to maintain the commercial momentum established in the first quarter while managing its cash position. The success of the OneRF platform in treating trigeminal neuralgia could provide proof-of-concept for applications in other chronic pain conditions, potentially expanding the total addressable market for NeuroOne's technology.
The broader medical device sector has shown increasing interest in minimally invasive pain treatments, as patients and physicians seek alternatives to opioid medications and more invasive surgical procedures. NeuroOne's early clinical results position it to compete in this growing market segment, though the company will need to demonstrate continued execution to maintain investor confidence.